CARY, N.C., June 2, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Deciphera Pharmaceuticals as a specialty pharmacy provider for QINLOCK™ (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
QINLOCK, approved by the FDA on May 15, 2020, is for patients who have a significant unmet medical need despite currently available therapies. Because more than 90% of individual metastatic KIT-driven GIST patients experience multiple mutations that cause their disease to progress, this disease is often resistant to existing therapies as they fail to inhibit all known mutations. QINLOCK was designed to inhibit the complete spectrum of known mutations in KIT and platelet-derived growth factor receptor A (PDGFRA).
“We are honored to make this significant new therapy available to GIST patients who have progressed on or are intolerant to established GIST therapies,” said Brandon Tom, vice president of Commercial Services for Biologics. “Because we have access to all oral treatments for GIST, the addition of QINLOCK to the Biologics portfolio means we can maintain continuity of care—and even the same care team—for patients who have tried a previous therapy and need to switch to this one.”
Biologics specialty pharmacy is committed to and recognized for its quality level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply-skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
About Biologics by McKesson
Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.
Claire Crye, Public Relations